^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SJCAR19
i
Other names: SJCAR19, CD19- specific CAR engineered autologous T-cells, SJCAR-19, SJCAR 19
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
St. Jude Children's Research Hospital
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
15d
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1/2, N=24, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Jul 2024 --> Jul 2025
Trial completion date
|
CD19 expression
|
cyclophosphamide • fludarabine IV • mesna • SJCAR19
over1year
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1/2, N=35, Recruiting, St. Jude Children's Research Hospital | Active, not recruiting --> Recruiting
Enrollment open
|
CD19 expression
|
cyclophosphamide • fludarabine IV • mesna • SJCAR19
almost2years
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1/2, N=35, Active, not recruiting, St. Jude Children's Research Hospital | Recruiting --> Active, not recruiting
Enrollment closed
|
CD19 (CD19 Molecule)
|
CD19 expression
|
cyclophosphamide • fludarabine IV • mesna • SJCAR19
Share via
